Joanna Tieu
Rituximab for maintenance of remission in ANCA-associated vasculitis: Expert consensus guidelines - Executive summary
Tieu, Joanna; Smith, Rona; Basu, Neil; Brogan, Paul; D’Cruz, David; Dhaun, Neeraj; Flossmann, Oliver; Harper, Lorraine; Jones, Rachel B.; Lanyon, Peter C.; Luqmani, Raashid A.; McAdoo, Stephen P.; Mukhtyar, Chetan; Pearce, Fiona A.; Pusey, Charles D.; Robson, Joanna C.; Salama, Alan D.; Smyth, Lucy; Watts, Richard A.; Willcocks, Lisa C.; Jayne, David R. W.
Authors
Rona Smith
Neil Basu
Paul Brogan
David D’Cruz
Neeraj Dhaun
Oliver Flossmann
Lorraine Harper
Rachel B. Jones
Peter C. Lanyon
Raashid A. Luqmani
Stephen P. McAdoo
Chetan Mukhtyar
Fiona A. Pearce
Charles D. Pusey
Jo Robson Jo.Robson@uwe.ac.uk
Consultant Associate Professor in Rheumatology
Alan D. Salama
Lucy Smyth
Richard A. Watts
Lisa C. Willcocks
David R. W. Jayne
Abstract
© 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) encompasses three disease phenotypes: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Considerable improvements in therapy mean induction of remission occurs in most patients with AAV [1-4]. However, disease relapse continues to pose a burden to patients. Morbidity accrues with relapses through disease-related damage and adverse effects of therapies to manage these relapses, negatively impacting on quality of life [5]. Rituximab (RTX), a monoclonal antibody targeting CD20, leads to peripheral B cell depletion. This has been successfully trialled, and is licensed, for the induction and maintenance of remission in AAV [2, 3]. RTX is increasingly being used for the maintenance of remission in patients with AAV, to reduce the risk of relapse and its consequences [6]. Other commonly used agents that have been trialled for the maintenance of remission in AAV include azathioprine, methotrexate and mycophenolate [7-9]. The decision to select RTX for the maintenance of remission is multifactorial, including but not limited to, patient-related factors and preferences, previous treatment and response, consideration of the overall risk of relapse, and access to therapy. These guidelines have been developed by a group of physicians practising in the UK.
Citation
Tieu, J., Smith, R., Basu, N., Brogan, P., D’Cruz, D., Dhaun, N., …Jayne, D. R. W. (2020). Rituximab for maintenance of remission in ANCA-associated vasculitis: Expert consensus guidelines - Executive summary. Rheumatology, 59(4), 727-731. https://doi.org/10.1093/rheumatology/kez632
Journal Article Type | Article |
---|---|
Acceptance Date | Nov 19, 2019 |
Online Publication Date | Feb 24, 2020 |
Publication Date | Apr 1, 2020 |
Deposit Date | May 15, 2020 |
Publicly Available Date | Feb 25, 2021 |
Journal | Rheumatology |
Print ISSN | 1462-0324 |
Electronic ISSN | 1462-0332 |
Publisher | Oxford University Press (OUP) |
Peer Reviewed | Peer Reviewed |
Volume | 59 |
Issue | 4 |
Pages | 727-731 |
DOI | https://doi.org/10.1093/rheumatology/kez632 |
Keywords | Pharmacology (medical); Rheumatology |
Public URL | https://uwe-repository.worktribe.com/output/5975247 |
Files
Rituximab for maintenance of remission in ANCA associated vasculitis: expert consensus guidelines
(1.1 Mb)
PDF
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Publisher Licence URL
http://www.rioxx.net/licenses/all-rights-reserved
Copyright Statement
This is a pre-copyedited, author-produced version of an article accepted for publication in Rheumatology following peer review. The version of record Joanna Tieu, Rona Smith, Neil Basu, et al, Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines—Executive summary, Rheumatology, Volume 59, Issue 4, April 2020, Pages 727–731, is available online at: https://academic.oup.com/rheumatology/article/59/4/727/5754009 or https://doi.org/10.1093/rheumatology/kez632
You might also like
ANCA associated vasculitis subtypes: Response (response to letter)
(2022)
Journal Article
Reply - October 2022
(2022)
Journal Article
Comment on: Benchmarking tocilizumab use for giant cell arteritis
(2022)
Journal Article
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search